Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.
Latest News
FDA Proposal for Biosimilar Use in 2025 Budget
A proposal for biosimilar use in the 2025 budget would allow substitution of any biosimilar for its reference product without an interchangeable designation. The hope…
The Biases We Don’t Know We Hold
Implicit bias can affect patient care at the physician level when they’re making treatment decisions and at the healthcare organization level when they’re choosing new hires. Here are insights into strategies rheumatologists can use to become aware of, and question, their implicit biases.
Mental Health in Rheumatology
Regaining a sense of control, limiting responsibilities and engaging in mindfulness can help rheumatologists manage their mental health needs. Rheumatologists should also address the mental health concerns raised by their patients. Here are insights from a psychiatrist/rheumatologist.
ACR Voices Support for the Healthcare Workforce Resilience Act
The ACR joined with 52 organizations in thanking House and Senate leaders for introducing the Healthcare Workforce Resilience Act, which would support employment-based visas for international physicians and nurses.
Spring 2024 State Legislative Update
The ACR is actively monitoring more than 60 pieces of legislation, focusing on such key issues as copay accumulators, utilization management reform, gold card programs and other emerging concerns. Two states have passed utilization management reform bills this year.
Rheum for Everyone, Episode 6: What Others Hear When You Ask ’Where Are You From’
In this episode, Dr. Kumar discusses brief, everyday exchanges that send denigrating messages to certain individuals because of their group membership.
The SMILE Online Lupus Tool Can Aid Shared Decision Making
Patients with systemic lupus erythematosus (SLE) often face many concerns, fears and uncertainties that render “treatment decision making very difficult,” says Jasvinder Singh, MD, MPH,…
‘Where Are You From?’ & Other Microaggressions
“I’m actually from Iowa. Where do you hail from?” I replied, in the friendliest tone I could muster. Many readers may already know the context,…